ArticleCell biochemistry and function2026
Integrated RNA Sequencing and Multi-Bioinformatics Analyses Reveal the Molecular Mechanisms Underlying the Anti-Breast Cancer Effects of the Fritillariae Thunbergii Bulbus-Bolbostemmatis Rhizoma Herb Pair.
Article in Cell biochemistry and function, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Breast cancer (BC) is a highly heterogeneous malignancy with complex molecular mechanisms, highlighting the need for effective biomarkers and therapeutic targets. The Fritillariae Thunbergii Bulbus-Bolbostemmatis Rhizoma (ZBM-TBM) herb pair has been used in the treatment of BC, although its potential molecular mechanisms remain incompletely understood. In this study, an integrated strategy combining transcriptomic analysis, machine learning, liquid chromatography-tandem mass spectrometry (LC-MS/MS), network pharmacology, molecular docking, molecular dynamics (MD) simulations, and single-cell virtual knockout analysis was employed to identify BC-associated molecular biomarkers and explore the potential mechanisms underlying the effects of ZBM-TBM. Integration of weighted gene co-expression network analysis with least absolute shrinkage and selection operator regression, random forest, and support vector machine-recursive feature elimination identified EPCAM as the only common core gene. EPCAM was significantly upregulated in BC tissues and showed favorable diagnostic performance (AUC = 0.903), while high EPCAM expression was associated with shorter overall survival (log-rank P = 0.032). Functional analyses indicated that EPCAM was associated with tumor-related and immune-related biological processes, including cell cycle regulation, DNA replication, and immune regulation. LC-MS/MS analysis identified 32 major active constituents of ZBM-TBM, and subsequent network pharmacology analysis identified 33 overlapping targets and 10 hub genes enriched in multiple tumor- and immune-related signaling pathways, including the Notch, IL-17, HIF-1, and TGF-β signaling pathways. Although ZBM-TBM did not directly target EPCAM in the predicted target network, computational analyses indicated functional associations between EPCAM and hub gene-associated regulatory networks. Molecular docking and MD simulations further suggested that peiminine may represent a potential active constituent, exhibiting favorable predicted binding characteristics with multiple candidate targets, particularly AURKA. Single-cell virtual knockout analysis showed that computational perturbation of AURKA was associated with alterations in cell cycle-, extracellular matrix-, and cell adhesion-related processes, supporting its potential functional relevance at the cellular level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.